Saving changes...

Done

Error

Articaine and Paresthesia in Dental Anesthesia: Neurotoxicity or Procedural Trauma?

Articaine and Paresthesia in Dental Anesthesia: Neurotoxicity or Procedural Trauma?

Articaine and Paresthesia in Dental Anesthesia: Neurotoxicity or Procedural Trauma?

Dr. M. Toma, Dr. M. Berghahn, S. Loth, B. Verrengia, Dr. L. Visani And F. Velotti
Dr. M. Toma, Dr. M. Berghahn, S. Loth, B. Verrengia, Dr. L. Visani And F. Velotti
on behalf of Dental Town

$36.00 $ 36.00 $ 36.00

$36.00 $ 36.00 $ 36.00

$ 36.00 $ 36.00 $ 36.00
$ 36.00 $ 36.00 $ 36.00
Normal Price: $36.00 $36.00

Review:

Launch date: 08 Mar 2017
Expiry Date:

Last updated: 08 Mar 2017

Reference: 170257

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

Description

This course is designed to educate the dental health professional concerning the occurrence and overall incidence of reported local anesthetic-induced paresthesia. In addition, it will serve to illustrate the potential causes of such paresthesia and to investigate whether the use of articaine is related to a higher frequency of occurrences of these adverse events.

Objectives

Objectives
Form an opinion concerning whether there is sufficient data to suggest an increased incidence of neurological side effects associated with the use of articaine. Attain an awareness of other potential causes of neurological effects in patients undergoing local anesthesia. Consider and evaluate the overall risk of local anesthetics in general as a significant contributor to neurologic adverse events. Consider additional risk factors paresthesia might be attributed to in local anesthesia, like procedural trauma and experience of dentist. Understand why randomization is the design of choice for clinical trials as it provides the most reliable results when investigating the risk of paresthesia after use of anesthetics.
Dr. M. Toma, Dr. M. Berghahn, S. Loth, B. Verrengia, Dr. L. Visani And F. Velotti

Author Information Play Video Bio

Dr. M. Toma, Dr. M. Berghahn, S. Loth, B. Verrengia, Dr. L. Visani And F. Velotti
on behalf of Dental Town

Dr. Mihaela Toma, graduated physician, has been working in the field of CRO industry, gaining experience in the fields of Pharmacovigilance, Regulatory Affairs and Quality Assurance. She joined Pierrel Research in 2005. Dr. Toma is currently Drug Safety Officer and Quality Management Manager. She has a degree of specialist physician in Internal Medicine. She has also gained a Doctorate MD awarded by the Medical Faculty of the University of Zurich, Switzerland. Dr. Michael Berghahn has a degree in chemistry and also gained an MSc in Pharmaceutical Medicine. He has been working in the field of clinical research since 2004 with a focus on clinical operations and pharmacovigilance. Today Dr. Berghahn is Director of Pharmacovigilance and Medical Services at Pierrel Research Europe GmbH, Germany. Stefan Loth holds a degree in biology and gained further qualification as scientific editor. He got into the biomedical industry working for a media agency. His medical writing career started by joining Pierrel Research Europe in 2006. Mr. Loth regularly writes publications for scientific journals and develops the documents for drug development programs of Pierrel customers. He is a member of the European Medical Writers Association (EMWA). Bernardo Verrengia was educated in the U.K. and gained an Honors Degree in Chemistry at The Royal Institute of Chemistry. In 1974 he was engaged by Albright and Wilson as Research Analyst in their R&D Department and later by VG instruments as mass spectrometry applications specialist. In 1982 he moved to Italy with Pierrel as Head of Analytical Chemistry in the Pharmaceuticals R&D Department. He has been actively involved in many R&D projects on new pharmacologically active chemical entities with NDA submissions and approvals in Europe, Canada, Russia and The USA. He has held positions of Site Manager and Qualified Person for many years within the Pharmacia Group, with main experience in the development and manufacturing of loco-regional anaesthetics. Today he is the Scientific and Regulatory Officer at Pierrel SpA. For further information please contact b.verrengia@pierrelgroup.com. Dr. Luigi Visani is doctor in medicine and specialist in cardiology. For about 13 years he has served as Director of Clinical Research of the Italian Operative Unit at Boehringer Ingelheim Italy. In 1998, he took the position of Managing Director at Hyperphar Group, (now Pierrel Research Italy), a leading CRO in Italy. Member of the Board of Directors of Pierrel SpA from December 2008 until January 2011, CEO of Pierrel SpA. Currently chairman and CEO of Pierrel Research International AG and CEO of Pierrel Research Europe GmbH. Fabio Velotti was educated at the Federico II University, in Naples (Italy) and gained a master’s of science degree in engineering. In 1999 he was engaged by DSM Royal Dutch where he covered several positions, basically focused on the development, manufacturing and commercialisation of pharma biotech products. In 2011 he moved to Pierrel in order to manage Pierrel pharmaceuticals products portfolio. Today he is the CEO at Pierrel Pharma. For further information, please contact f.velotti@pierrelgroup.com.

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Academy of General Dentistry (PACE)
  • 1.50 Hours

Faculty and Disclosures

Additional Contributors

null

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error